Acurx Pharmaceuticals (ACXP) vs AIM ImmunoTech (AIM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
AIM ImmunoTech is the larger company by market cap ($7.2 million vs $6.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACXP | AIM |
|---|---|---|
| Share price | $1.25 | $0.1796 |
| Market cap | $6.95M | $7.17M |
| 1-day change | -3.85% | -1.75% |
| EPS (TTM) | $-2.67 | $-3.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.98 | $2.79 |
| 52-week low | $1.23 | $0.17 |
| Distance from 52-week high | -84.34% | -93.57% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1260.00% | +2266.37% |
| Average volume | 125.08K | 4.70M |
| Shares outstanding | 5.56M | 39.89M |
| Employees | 4 | 19 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Acurx Pharmaceuticals
ACXP stock →Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About AIM ImmunoTech
AIM stock →AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees
ACXP vs AIM FAQ
Which is bigger, Acurx Pharmaceuticals or AIM ImmunoTech?
AIM ImmunoTech (AIM) is larger, with a market capitalization of $7.17M compared with $6.95M for Acurx Pharmaceuticals (ACXP).
Are Acurx Pharmaceuticals and AIM ImmunoTech in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Acurx Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for AIM ImmunoTech.